News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,363 Results
Type
Article (31503)
Company Profile (259)
Press Release (664591)
Multimedia
Podcasts (100)
Webinars (16)
Section
Business (222722)
Career Advice (1033)
Deals (33960)
Drug Delivery (114)
Drug Development (75586)
Employer Resources (73)
FDA (14925)
Job Trends (12746)
News (323472)
Policy (26174)
Tag
2025 Best Places to Work (14)
2026 Best Places to Work (23)
2027 BioCapital Standard (3)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (5)
2027 Pharm Country Standard (5)
40 Under 40 (3)
Academia (2091)
Academic (1)
Accelerated approval (60)
ADA (37)
Adcomms (18)
Allergies (201)
Alliances (49924)
ALS (250)
Alzheimer's disease (1867)
Antibody-drug conjugate (ADC) (725)
Approvals (15818)
Artificial intelligence (963)
ASCO (299)
Autoimmune disease (482)
Automation (76)
Bankruptcy (315)
Belgium (41)
Best Places to Work (10138)
BIO (64)
Biologics (116)
BIOSECURE Act (14)
Biosimilars (208)
BioSpace Insights (135)
Biotechnology (175)
Bispecific (62)
Bladder cancer (210)
Brain cancer (96)
Breast cancer (905)
Cancer (7320)
Cardiovascular disease (543)
Career advice (891)
Career pathing (24)
CAR-T (425)
CDC (30)
CDMO (172)
Celiac Disease (7)
Cell-line development (2)
Cell therapy (1097)
Cervical cancer (62)
Clinical research (68076)
Collaboration (2662)
Commercialization (64)
Company closure (4)
Compensation (1794)
Complete response letters (68)
COVID-19 (2025)
CRISPR (147)
CRO (7)
C-suite (1488)
Cystic fibrosis (152)
Data (10453)
Decentralized trials (3)
Denatured (37)
Depression (165)
Dermatology (177)
Diabetes (653)
Diagnostics (7251)
Digital health (76)
Diversity (7)
Diversity, equity & inclusion (15)
Drug discovery (461)
Drug pricing (80)
Drug shortages (12)
Duchenne muscular dystrophy (291)
Earnings (89208)
Editorial (32)
Employer branding (11)
Employer resources (69)
ESMO (410)
Events (118468)
Executive appointments (1207)
Eye disease (20)
FDA (19644)
Fibrodysplasia Ossificans Progressiva (14)
Fragile X (4)
Friedreich's ataxia (26)
Frontotemporal dementia (40)
Funding (2131)
Gene editing (299)
Generative AI (80)
Gene therapy (784)
GLP-1 (869)
Government (2675)
Grass and pollen (4)
Guidances (406)
Healthcare (16030)
Hematology (200)
HIV (103)
Huntington's disease (65)
Idiopathic pulmonary fibrosis (14)
IgA nephropathy (143)
Immunology and inflammation (339)
Immuno-oncology (144)
Indications (276)
Infectious disease (2393)
Inflammatory bowel disease (255)
Inflation Reduction Act (8)
Influenza (148)
Intellectual property (373)
Interviews (137)
IPO (15953)
IRA (24)
Job creations (2989)
Job search strategy (758)
JPM (41)
Kidney cancer (26)
Kidney disease (153)
Labor market (50)
Layoffs (335)
Leadership (24)
Legal (6329)
Licensing (127)
Liver cancer (101)
Longevity (49)
Lung cancer (1007)
Lung diease (19)
Lymphoma (528)
Machine learning (72)
Management (28)
Manufacturing (1303)
Marketing (39)
MASH (223)
Medical affairs (4)
Medical device (14067)
Medtech (14401)
Melanoma (142)
Mergers & acquisitions (19487)
Metabolic disorders (1530)
Middle East (2)
mRNA (293)
Multiple sclerosis (228)
Multispecific (7)
NASH (15)
Netherlands (34)
Neurodegenerative disease (531)
Neuropsychiatric disorders (95)
Neuroscience (3702)
Neurotech (3)
NextGen: Class of 2026 (5481)
Non-profit (2625)
Now hiring (34)
Obesity (604)
Opinion (212)
Ovarian cancer (277)
Pain (308)
Pancreatic cancer (434)
Parkinson's disease (440)
Partnered (35)
Patents (750)
Patient advocacy (5)
Patient recruitment (921)
Patient selection (120)
Peanut (70)
People (56833)
Peptides (40)
Pharmaceutical (43)
Pharmacy benefit managers (23)
Phase 1 (22529)
Phase 2 (30380)
Phase 3 (21080)
Pipeline (13765)
Policy (165)
Postmarket research (1996)
Preclinical (9699)
Press Release (70)
Prostate cancer (377)
Psychedelics (46)
Radioligand (2)
Radiopharmaceuticals (421)
Rare diseases (1238)
Real estate (5141)
Recruiting (31)
Regenerative medicine (35)
Regulatory (23322)
Reports (44)
Research institute (2168)
Resumes & cover letters (200)
Rett syndrome (58)
RNA editing (35)
RSV (81)
Saudi Arabia (1)
Schizophrenia (193)
Series A (393)
Series B (263)
Series C (1)
Service/supplier (6)
Sickle cell disease (120)
Special edition (8)
Spinal muscular atrophy (153)
Sponsored (46)
Startups (3628)
State (2)
Stem cells (7)
Stomach cancer (16)
Substance use disorders (22)
Supply chain (110)
Switzerland (22)
Tariffs (34)
The Weekly (60)
Vaccines (980)
Venture capital (116)
Weight loss (318)
Wet AMD (7)
Women's health (146)
Worklife (6)
Date
Today (23)
Last 7 days (626)
Last 30 days (3437)
Last 365 days (29422)
2026 (27017)
2025 (28661)
2024 (33547)
2023 (38322)
2022 (48985)
2021 (52496)
2020 (49332)
2019 (39808)
2018 (29824)
2017 (29758)
2016 (28770)
2015 (35123)
2014 (29485)
2013 (25275)
2012 (27195)
2011 (27623)
2010 (26151)
Location
Africa (542)
Alabama (104)
Alaska (6)
Arizona (425)
Arkansas (17)
Asia (38544)
Australia (6324)
California (16448)
Canada (4457)
China (1801)
Colorado (718)
Connecticut (706)
Delaware (429)
Europe (79605)
Florida (2449)
Georgia (521)
Hawaii (4)
Idaho (60)
Illinois (1233)
India (119)
Indiana (620)
Iowa (31)
Japan (751)
Kansas (145)
Kentucky (54)
Louisiana (59)
Maine (81)
Maryland (1841)
Massachusetts (11892)
Michigan (439)
Minnesota (852)
Mississippi (7)
Missouri (177)
Montana (32)
Nebraska (19)
Nevada (197)
New Hampshire (91)
New Jersey (4057)
New Mexico (33)
New York (4185)
North Carolina (1962)
North Dakota (14)
Northern California (8382)
Ohio (468)
Oklahoma (26)
Oregon (47)
Pennsylvania (3167)
Puerto Rico (31)
Rhode Island (62)
South America (811)
South Carolina (101)
South Dakota (1)
Southern California (6742)
Tennessee (242)
Texas (2750)
United States (56985)
Utah (505)
Vermont (2)
Virginia (377)
Washington D.C. (59)
Washington State (1274)
West Virginia (3)
Wisconsin (180)
Wyoming (4)
696,363 Results for "molecular targeting technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
VedaBio Demonstrates Under-10-Minute Molecular Detection with Target Amplification-Free CRISPR Technology at AMP 2026
November 15, 2026
·
2 min read
Press Releases
Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™
September 1, 2026
·
9 min read
Press Releases
New Innovative Molecular Technology Combination “LAMP + CRISPR” as CE-IVD
October 20, 2026
·
2 min read
Press Releases
Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026
May 28, 2026
·
2 min read
Press Releases
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
October 29, 2026
·
5 min read
Deals
Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap
Evommune is commiting $30 million upfront for Hinova Pharmaceuticals’ oral molecular glue degrader—a low-cost bet with a high probability of success, according to analysts, after clinical failures roiled the biotech’s internal pipeline earlier this year.
November 5, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
November 18, 2026
·
10 min read
Press Releases
VedaBio Selects UCP Merchant Medicine to Position Its Target Amplification-Free CRISPR Molecular Diagnostics for Urgent Care
September 1, 2026
·
7 min read
Press Releases
Insight Molecular Diagnostics Announces Proposed Public Offering
November 16, 2026
·
4 min read
Press Releases
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 27, 2026
·
3 min read
1 of 69,637
Next